Antibody Discovery Ex Vivo Accelerated by the LacO/LacI Regulatory Network.
|Title||Antibody Discovery Ex Vivo Accelerated by the LacO/LacI Regulatory Network.|
|Publication Type||Journal Article|
|Year of Publication||2012|
|Authors||Yabuki M, Cummings JW, Leppard JB, Immormino RM, Wood CL, Allison DS, Gray PW, Tjoelker LW, Maizels N|
Monoclonal antibodies (mAbs) can be potent and highly specific therapeutics, diagnostics and research reagents. Nonetheless, mAb discovery using current in vivo or in vitro approaches can be costly and time-consuming, with no guarantee of success. We have established a platform for rapid discovery and optimization of mAbs ex vivo. This DTLacO platform derives from a chicken B cell line that has been engineered to enable rapid selection and seamless maturation of high affinity mAbs. We have validated the DTLacO platform by generation of high affinity and specific mAbs to five cell surface targets, the receptor tyrosine kinases VEGFR2 and TIE2, the glycoprotein TROP2, the small TNF receptor family member FN14, and the G protein-coupled receptor FZD10. mAb discovery is rapid and humanization is straightforward, establishing the utility of the DTLacO platform for identification of mAbs for therapeutic and other applications.
|Alternate Journal||PLoS ONE|